Avycaz® (ceftazidime/avibactam) – Expanded indication
December 20, 2022, the FDA approved Allergan’s Avycaz (ceftazidime/avibactam) injection, for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adult and pediatric patients aged 3 months and older caused by the following susceptible gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae.
Top